Allergic reactions to clopidogrel and cross-reactivity to other agents

Juzar Lokhandwala, Patricia J.M. Best, Yvette Henry, Peter B. Berger

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Clopidogrel is a widely used antiplatelet agent, particularly after coronary stent implantation. About 1% of patients have allergic or hematologic adverse reactions to clopidogrel. This has important therapeutic implications, as premature discontinuation of clopidogrel is the strongest risk factor for stent thrombosis. Clopidogrel allergy most commonly manifests as a rash. It is important to distinguish this from other causes of rash occurring in patients who have had a recent coronary stent. Although antihistamines and short-term oral corticosteroids are effective in treating most clopidogrel hypersensitivity reactions, some persistent reactions may require discontinuation of clopidogrel. When discontinuation of clopidogrel is required, substitution with an alternative thienopyridine such as ticlopidine traditionally has been performed. However, a recent study suggests that there may be as high as a 27% risk of recurrence of non-life-threatening allergic reactions in such patients, which are usually similar to the allergic reactions that occurred with clopidogrel. No data are available regarding the frequency of cross-reactivity to prasugrel and ticagrelor; these may be potential therapeutic options in some patients.

Original languageEnglish (US)
Pages (from-to)52-57
Number of pages6
JournalCurrent Allergy and Asthma Reports
Issue number1
StatePublished - Feb 2011


  • Allergy
  • Clopidogrel
  • Cross-reactivity
  • Desensitization
  • Thienopyridine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Allergic reactions to clopidogrel and cross-reactivity to other agents'. Together they form a unique fingerprint.

Cite this